Literature DB >> 20025546

Signaling defects and functional impairment in T-cells from cervical cancer patients.

Vino T Cheriyan1, Smriti M Krishna, Aswin Kumar, Puthuveetil Govindan Jayaprakash, Prabha Balaram.   

Abstract

The ability of T-lymphocytes to recognize antigens and transduce signals to the nucleus successfully is a key component in the initiation and maintenance of an immune response. The present study addressed the expression status of the signal-transducing proteins in relation to the immune impairment in cervical cancer patients. Immune response was measured by evaluating lymphocyte subpopulations CD3(+), CD4(+), and CD8(+), using flowcytometry, natural killer cell activity, using the single-cell cytotoxicity assay, lymphocyte function, using mitogenic response to PHA and T-cell activation following anti-CD3 stimulation, and production of IL-2. Expression of the T-cell signal transduction proteins, TCR-zeta, CD3-epsilon, zap-70, p(56)lck, PKC, NFkappabeta p50, Rel-A, Rel-B, and c-rel, was evaluated by using Western blot assay. A generalized depression of the immune response with respect to the different parameters evaluated was observed. Exogenous interleukin-2 (IL-2) could increase the response in all the controls and in 30% of the patients to different degrees varying from 10% to 90%. Low levels of the signaling molecules (TCR-zeta, CD3-epsilon, zap-70, p(56)lck, and PKC) and impairment in the transduction of NFkappabeta components (p50, Rel-A, Rel-B, and c-rel) to the nuclei were observed in these lymphocytes. Decreased CD4(+)/CD8(+) ratio with an increase in suppressor cells, reduced lymphocyte proliferation, and production of IL-2 suggest a defective immune regulation in cervical cancer. Impairment in the translocation of NFkappabeta p50, Rel-A, and Rel-B to the nucleus and the reduced levels of signal-transducing proteins might be responsible for the decreased production of IL-2 and immune impairment in cervical cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20025546     DOI: 10.1089/cbr.2009.0660

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  9 in total

1.  Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.

Authors:  Susan K Lutgendorf; Elizabeth Mullen-Houser; Daniel Russell; Koen Degeest; Geraldine Jacobson; Laura Hart; David Bender; Barrie Anderson; Thomas E Buekers; Michael J Goodheart; Michael H Antoni; Anil K Sood; David M Lubaroff
Journal:  Brain Behav Immun       Date:  2010-06-30       Impact factor: 7.217

2.  Location and Density of Immune Cells in Precursor Lesions and Cervical Cancer.

Authors:  Astrid M Bedoya; Roberto Jaramillo; Armando Baena; Jorge Castaño; Natalia Olaya; Arnold H Zea; Rolando Herrero; Gloria I Sanchez
Journal:  Cancer Microenviron       Date:  2012-01-31

3.  Heat shock protein 10 (Hsp10) in immune-related diseases: one coin, two sides.

Authors:  Haibo Jia; Amadou I Halilou; Liang Hu; Wenqian Cai; Jing Liu; Bo Huang
Journal:  Int J Biochem Mol Biol       Date:  2010-12-25

4.  Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy.

Authors:  Vino T Cheriyan; Cessal Thomas; Prabha Balaram
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

Review 5.  Viral Infections, the Microbiome, and Probiotics.

Authors:  Ashton Harper; Vineetha Vijayakumar; Arthur C Ouwehand; Jessica Ter Haar; David Obis; Jordi Espadaler; Sylvie Binda; Shrilakshmi Desiraju; Richard Day
Journal:  Front Cell Infect Microbiol       Date:  2021-02-12       Impact factor: 6.073

6.  Exosome removal as a therapeutic adjuvant in cancer.

Authors:  Annette M Marleau; Chien-Shing Chen; James A Joyce; Richard H Tullis
Journal:  J Transl Med       Date:  2012-06-27       Impact factor: 5.531

Review 7.  The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next?

Authors:  Anita Mitra; David A MacIntyre; Julian R Marchesi; Yun S Lee; Phillip R Bennett; Maria Kyrgiou
Journal:  Microbiome       Date:  2016-11-01       Impact factor: 14.650

8.  Cervicovaginal microbiota significantly changed for HPV-positive women with high-grade squamous intraepithelial lesion.

Authors:  Chunlei Guo; Wenkui Dai; Qian Zhou; Liming Gui; Han Cai; Di Wu; Jun Hou; Changzhong Li; Shuaicheng Li; Hui Du; Ruifang Wu
Journal:  Front Cell Infect Microbiol       Date:  2022-08-04       Impact factor: 6.073

9.  The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions.

Authors:  Anita Mitra; David A MacIntyre; George Ntritsos; Ann Smith; Konstantinos K Tsilidis; Julian R Marchesi; Phillip R Bennett; Anna-Barbara Moscicki; Maria Kyrgiou
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.